A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
Children's Hospital Medical Center, Cincinnati · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06028113
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 0 mo+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 144
- US sites recruiting
- 1
- Study start
- October 5, 2023
- Record last updated
- March 5, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to test a responsive parenting obesity prevention program with infants and caregivers of color (e.g., non-White; Hispanic/Latinx) and/or who are economically marginalized (i.e., publicly insured), delivered via Integrated Behavioral Health (IBH) in pediatric primary care. The main questions it aims to answer are:
- 1) Is the obesity prevention intervention delivered via IBH in pediatric primary care feasible and acceptable to families of color and/or families who are economically marginalized?
- 2) Will it prevent rapid weight gain during infancy?
Participants will complete baseline (newborn), post-treatment (9 months), and follow-up assessments (12 months). Participants assigned to treatment will receive 4 prevention sessions as part of their typical well-child visit in pediatric primary care. Researchers hypothesize that infants in the obesity prevention intervention will have stable weight gain compared to infants in the control group (treatment as usual) will experience more rapid weight gain.
Being studied: THRIVE 2.0
Conditions: Obesity; Obesity, Childhood; Weight Gain; Weight Gain Trajectory
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- born 2500 grams or greater
- delivery occurring between 37 and 42 weeks gestation
- English speaking
- infant receiving care provided at our pediatric primary care setting
- from a racial / ethnic minority group (i.e., non-white, or Hispanic or Latinx) and/or economically marginalized background (i.e., household income at or below 138% of federal poverty level; qualifying for Medicaid)
Exclusion Criteria
- care in the Neonatal Intensive Care Unit (>7 days)
- infant congenital anomaly or neonatal condition that affects feeding (e.g., cleft lip/palate, metabolic disease)
- infant exposure to illicit drugs in utero [with the exception of tetrahydrocannabinol (THC)]
- diminished or impaired caregiver cognitive functioning
- family intent to move from the area within 1 year
Recruiting US locations
Hopple Street Neighborhood Health Center
Cincinnati, OH 45225
Site contact: Sarah Francis · sarah.francis@cchmc.org
Study contacts (from the official record)
- Tiffany Rybak, PhD · 513-517-7254 · tiffany.rybak@cchmc.org
- Sarah Francis, PhD · 513-803-2605 · sarah.francis@cchmc.org
Similar studies in Ohio
All weight loss studies in Ohio →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
Hanmi Pharmaceutical Company Limited
- Location
- Cincinnati, OH
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Columbus, OH + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Cincinnati, OH + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Pfizer
- Location
- Cincinnati, OH + 4 other US sites
- Eligibility basics
- Ages 18+